Vertex Pharmaceuticals (VRTX) Finished Goods (2011 - 2012)
Vertex Pharmaceuticals (VRTX) posted quarterly Finished Goods of $23.3 million for Q3 2012, up 94.18% year-over-year from $12.0 million in Q4 2011, and down 0.81% quarter-over-quarter from $23.5 million in Q2 2012.
Powered by 
Analysis
Vertex Pharmaceuticals (VRTX) Finished Goods (2011 - 2012) Analysis & Trends
Vertex Pharmaceuticals' Finished Goods history runs 2 years deep, the most recent figure standing at $23.3 million for Q3 2012.
- In Q3 2012, Finished Goods rose 94.18% year-over-year to $23.3 million; the TTM figure through Sep 2012 stood at $23.3 million (up 94.18% YoY), while the FY2011 annual figure was $33.2 million, changed N/A from the prior year.
- Finished Goods for Q3 2012 stood at $23.3 million, down from $23.5 million in the prior quarter.
- The five-year high for Finished Goods was $33.2 million in Q4 2011, with the low at $12.0 million in Q3 2011.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn |
| 10 | Incyte | 25.61 Bn | 21.07 Bn | 1.57 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2012 | 23.32 Mn |
| Jun 30, 2012 | 23.51 Mn |
| Mar 31, 2012 | 26.35 Mn |
| Dec 31, 2011 | 33.21 Mn |
| Sep 30, 2011 | 12.01 Mn |